Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bicalutamide + Docetaxel + Flutamide + Goserelin + Leuprolide + Nilutamide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bicalutamide||Casodex||Hormone - Anti-androgens 38||Casodex (bicalutamide) is an androgen-receptor antagonist that binds androgen receptors and inhibits androgen binding, therefore inhibits AR-dependent growth of tumor cells (PMID: 9428389). Casodex (bicalutamide) is approved, in combination with a luteinizing hormone-releasing hormone (LHRH) analog, for metastatic carcinoma of the prostate (FDA.gov).|
|Docetaxel||Taxotere||RP56976||Antimicrotubule Agent 13||Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558).|
|Flutamide||Eulexin||Flutamide USP25||Hormone - Anti-androgens 38||Eulexin (flutamide) is a nonsteroidal antiandrogen that competitively blocks androgen receptors. Eulexin prevents receptor activation and translocation to the nucleus, thus preventing androgen-dependent DNA and protein synthesis, which may prevent tumor cell growth (NCI Drug Dictionary).|
|Goserelin||Zoladex||Goserelin acetate||Zoladex (goserelin) is a synthetic analog of lutenizing hormone-releasing hormone, which causes decreased testosterone production in males and decreased estradiol production in females, and is FDA approved for use in prostate carcinoma (FDA.gov).|
|Leuprolide||Lupron||Leuprorelin||Lupron (leuprolide) is an agonist of gonadotropin releasing hormone (GnRH), which results decreased testosterone production in males and decreased estradiol production in females, potentially leading to decreased growth of androgen-positive tumors (NCI Drug Dictionary).|
|Nilutamide||Nilandron||Anandron||Hormone - Anti-androgens 38||Nilandron (nilutamide) is a nonsteroidal antiandrogen, binding to the androgen receptor and blocking agonists, thereby inhibiting androgen-dependent tumor growth (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03070886||Phase III||Bicalutamide + Docetaxel + Flutamide + Goserelin + Leuprolide + Nilutamide Bicalutamide + Flutamide + Goserelin + Leuprolide + Nilutamide||Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery||Recruiting||USA | CAN||1|